发明授权
- 专利标题: Pyrrolopyrimidine and pyrrolotriazine derivatives
- 专利标题(中): 吡咯并嘧啶和吡咯并三嗪衍生物
-
申请号: US10584946申请日: 2005-01-06
-
公开(公告)号: US08106194B2公开(公告)日: 2012-01-31
- 发明人: Atsuro Nakazato , Taketoshi Okubo , Dai Nozawa , Tomoko Tamita , Ludo E. J. Kennis
- 申请人: Atsuro Nakazato , Taketoshi Okubo , Dai Nozawa , Tomoko Tamita , Ludo E. J. Kennis
- 申请人地址: JP Tokyo
- 专利权人: Taisho Pharmaceutical Co., Ltd.
- 当前专利权人: Taisho Pharmaceutical Co., Ltd.
- 当前专利权人地址: JP Tokyo
- 代理机构: Sughrue Mion, PLLC
- 优先权: JP2004-001311 20040106
- 国际申请: PCT/JP2005/000319 WO 20050106
- 国际公布: WO2005/066142 WO 20050721
- 主分类号: C07D251/02
- IPC分类号: C07D251/02 ; C07D251/42 ; C07D239/70
摘要:
An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc. A pyrrolopyrimidine or pyrrolotriazine derivative substituted with a carbamoyl group represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.
公开/授权文献
- US20110137031A1 PYRROLOPYRIMIDINE AND PYRROLOTRIAZINE DERIVATIVES 公开/授权日:2011-06-09
信息查询